NasdaqGS - Nasdaq Real Time Price USD

Century Therapeutics, Inc. (IPSC)

0.5754

-0.0246

(-4.10%)

At close: June 13 at 4:00:01 PM EDT

0.5909

+0.02

+(2.69%)

After hours: June 13 at 5:58:54 PM EDT

Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain

Century Therapeutics (IPSC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks 9 days ago

IPSC
-4.10%
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress

PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 11-14, 2025, at Fira de Barcelona in Barcelona, Spain. The presentations will highlight data supporting

GlobeNewswire 18 days ago

IPSC
-4.10%
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates

Century Therapeutics (IPSC) delivered earnings and revenue surprises of 387.10% and 139.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

IPSC
-4.10%
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Italy CNTY-308 expected to enter IND-enabling studies in mid-2025 to support anticipated clinical trials in B-cell-mediated autoimmune diseases and malignancies Presentations at ASGCT 28th Annual Meeting highlight preclinical pipeline anchored by advanced iPSC-derived ’tunable’ CD4+/CD8+ ab T cells and

GlobeNewswire last month

IPSC
-4.10%
Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Century Therapeutics (IPSC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

IPSC
-4.10%
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which is being held from May 13-17, 2025, at the New Orleans Ernest N. Morial Convention Center in New Orleans, LA. The presentations w

GlobeNewswire last month

IPSC
-4.10%
Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025

PHILADELPHIA, April 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that company management will host a live fireside chat on Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss details and data for its prioritized preclinical cell therapy programs targeting autoimmune diseases and cancer. The event will

GlobeNewswire last month

IPSC
-4.10%
Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock?

Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 2 months ago

IPSC
-4.10%
Century Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Century Therapeutics ( NASDAQ:IPSC ) Full Year 2024 Results Key Financial Results Net loss: US$126.6m (loss narrowed by...

Simply Wall St. 2 months ago

IPSC
-4.10%
Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates

Century Therapeutics (IPSC) delivered earnings and revenue surprises of 4.44% and 89.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

IPSC
-4.10%
Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies New concentrated clinical focus for CNTY-101 based on unique profile with transformational potential in autoimmune disease; data anticipated in 2025 Cash runway estimate extended into fourth quarter of 2026 PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC),

GlobeNewswire 2 months ago

IPSC
-4.10%
Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders

- Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group at Friedrich-Alexander University Erlangen-Nürnberg - - Trial to evaluate and enhance clinical experience with CNTY-101 in patients with systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy, and diffuse cutaneous systemic sclerosis - PHILADELPHIA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an inno

GlobeNewswire 4 months ago

IPSC
-4.10%
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that members of the management team will participate in the following events at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024: Autoimmune Disease Cell Therapy Panel: 3:00 PM ET Presenter: Chad Cowan, Ph.D., Chief

GlobeNewswire 6 months ago

IPSC
-4.10%
What Makes Century Therapeutics (IPSC) a New Buy Stock

Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 7 months ago

IPSC
-4.10%
Century Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Century Therapeutics ( NASDAQ:IPSC ) Third Quarter 2024 Results Key Financial Results Net loss: US$31.2m (loss narrowed...

Simply Wall St. 7 months ago

IPSC
-4.10%
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates

Century Therapeutics (IPSC) delivered earnings and revenue surprises of 19.57% and 69.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 7 months ago

IPSC
-4.10%
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy –– Overall response rate (ORR) of 83% observed at CNTY-101 Dose Level 3B alongside a favorable safety profile in patients with r/r B-cell lymphomas in Phase 1 ELiPSE-1 study –– CNTY-101 shows persistence upon repeated cell dosing at Dose Level 3B, consistent with the anticipated protective activity of Century’s proprietary Allo-Evasion™ tec

GlobeNewswire 7 months ago

IPSC
-4.10%
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting

– Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease (AID) – – Preclinical data on development of iPSC-derived CD4+ and CD8+ CAR T cells that demonstrate function comparable to primary αβ CAR-T cells, allowing for control of tumors in vivo without the need for exogenous or engineered cytokines – – Posters include demonstration of advances in gene editing and transgene design that enable greater control and

GlobeNewswire 7 months ago

IPSC
-4.10%
Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference

PHILADELPHIA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Chad Cowan, Ph.D., Chief Scientific Officer, will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 9:30am ET.

GlobeNewswire 7 months ago

IPSC
-4.10%
We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 7 months ago

IPSC
-4.10%

Performance Overview

Return	IPSC	S&P 500 (^GSPC)
YTD	-43.03%	+1.62%
1-Year	-82.35%	+10.00%
3-Year	-92.77%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Century Therapeutics, Inc. (IPSC)

Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain

Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress

Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates

Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025

Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock?

Century Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates

Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

What Makes Century Therapeutics (IPSC) a New Buy Stock

Century Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting

Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

Performance Overview